Fig. 4: Therapeutic effect of C20 in combination with ICI in two different schedules of vaccination.
From: Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
a Balb/c mice were inoculated s.c. with CT26 cells and treated with C20 and ICI starting from day 2 as depicted in the experimental scheme. Tumor volume and survival curve. b, c Balb/c mice were inoculated s.c. with CT26 cells and treated with ICI and NCV according to the experimental scheme. b Tumor (50–100 mm3) bearing mice were randomized at day 6 and treated with αCTLA-4 and vaccinated with C20 the day after. The treatment was repeated weekly as described in the scheme. b Tumor volume measurements and survival curve. This experiment was conducted only once (C) CT26 tumor growth in CD4 or CD8 depleted mice treated as in panel (b). This experiment was repeated twice with similar results. Six animals per group were utilized with the error bars representing the s.e.m. Significance was determined using Mann–Whitney and Log-rank (Mantel–Cox) test **p < 0.01 ***p < 0.001.
